Cantabio and Purdue Advance Treatment of Parkinson’s Disease

July 14, 2016 - Cantabio Pharmaceuticals, Inc. and the Purdue Research Foundation have signed an agreement to advance development work on targeting DJ-1 protein for treating Parkinson's diseases. Dr. Chris Rochet, Professor of Medicinal Chemistry and Molecular Pharmacology, has been working with Cantabio since 2009 on this research.  Read more here.

Mega Menu Visual Content